Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11186271 | 0.83 | TP53 (0.41) | TP53MAOBCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5165136 | 0.81 | MAOB (0.52) | TP53MAOBCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11380502 | 0.80 | TP53 (0.42) | TP53CYP1A2CYP3A4CYP2D6NOS1 | |
| SCHEMBL8409690 | 0.80 | IDO1 (0.44) | CYP1A2IDO1RAB9AGAATAAR1 | |
| SCHEMBL5272709 | 0.79 | CYP1A2 (0.39) | TP53MAOBCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8748289 | 0.79 | CYP2C19 (0.43) | TP53CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL19036474 | 0.78 | MAOB (0.44) | TP53MAOBCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8410255 | 0.78 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2D6NOS1HSD17B10 | |
| SCHEMBL11179571 | 0.78 | SIGMAR1 (0.41) | TP53 | |
| SCHEMBL5073225 | 0.77 | EPHX2 (0.42) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023101004-A1 | OLEFIN RESIN, METHOD FOR MANUFACTURING SAME, AND APPLICATION FOR SAME | 三井化学株式会社 | 2023-06-08 | — | — | WO | disclosed |
| US-9957272-B2 | 3-hydroxypyrrolidine inhibitors of 5′-methylthioadenosine phosphorylase and nucleosidase | VICTORIA LINK LIMITED (NZ) | 2018-05-01 | — | — | US | disclosed |
| US-20170166573-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | VICTORIA LINK LIMITED (NZ) | 2017-06-15 | — | — | US | disclosed |
| US-9493465-B2 | 3-hydroxypyrrolidine inhibitors of 5′-methylthioadenosine phosphorylase and nucleosidase | VICTORIA LINK LIMITED (NZ) | 2016-11-15 | — | — | US | disclosed |
| US-20120157479-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-06-21 | — | — | US | disclosed |
| EP-2454263-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | The Albert Einstein College Of Medicine Of Yeshiva University (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011008110-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | ALBERT EINSTEIN COLLEGE OF YESHIVA UNIVERSITY (US) | 2011-01-20 | — | — | WO | disclosed |
| US-4598155-A | 3(5-tetrazolyl)1,4-diaminoanthraquinones | CIBA-GEIGY CORPORATION (US) | 1986-07-01 | — | — | US | disclosed |
| EP-0079862-B1 | 1,4-DIAMINO-ANTHRAQUINONE COMPOUNDS | CIBA-GEIGY AG (CH) | 1986-01-15 | — | — | EP | disclosed |
| US-4393070-A | HYPOTENSIVE, VASODILATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-07-12 | — | — | US | disclosed |
| EP-0079862-A2 | 1,4-Diamino-anthraquinone compounds | CIBA-GEIGY AG (CH) | 1983-05-25 | — | — | EP | disclosed |
| US-4307103-A | TREATMENT OF HYPERTENSION AND CARDIOVASCULAR DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157479-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | TYMP, MTAP, PNP | TP53 1476/4885MAOB 1304/4885CYP1A2 1470/4885 |
| US-20170166573-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | TYMP, MTAP, PNP | TP53 1494/4885MAOB 1365/4885CYP1A2 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.